Related Experiment Video
Updated: Jun 27, 2026
06:58
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Knowing - or not knowing - when to stop: cognitive decline in ageing doctors
Robert G Adler1, Conn Constantinou
1Medical Practitioners Board of Victoria, Melbourne, VIC, Australia. Robert.Adler@medicalboardvic.org.au
The Medical Journal of Australia
|December 9, 2008
Summary
Many older doctors face cognitive decline, impacting safe practice. Clear guidelines are needed for medical boards to assess cognitive impairment risks in physicians.
Area of Science:
- Geriatrics
- Medical Ethics
- Neurology
Background:
- A significant proportion of registered medical practitioners are over 60, raising concerns about age-related cognitive changes and practice safety.
- Cognitive decline is a normal part of aging, potentially affecting medical professionals' ability to practice safely, especially with conditions like Mild Cognitive Impairment (MCI).
- Physicians with early dementia or MCI may lack self-awareness regarding their declining cognitive function and its impact on patient care.
Purpose of the Study:
- To explore the challenges doctors face in deciding when to cease practice due to cognitive decline.
- To examine the implications of cognitive impairment in medical practitioners for public safety.
- To highlight the absence of established guidelines for Medical Boards in assessing cognitive risks.
Main Methods:
- Review of demographic data on aging medical practitioners.
- Discussion of the relationship between normal aging, cognitive decline, Mild Cognitive Impairment (MCI), and dementia.
- Analysis of adaptive strategies doctors can employ to manage cognitive decline.
Main Results:
- A substantial percentage of doctors are over 60, indicating a growing demographic concern.
- Cognitive decline and MCI can impair a doctor's ability to practice safely, often without their full recognition.
- Doctors can implement coping mechanisms to extend their careers, but these do not negate underlying cognitive issues.
Conclusions:
- Medical Boards have a duty to protect the public from unsafe medical practice due to cognitive impairment.
- There is a critical need for agreed-upon guidelines to help Medical Boards determine acceptable levels of cognitive impairment in doctors.
- Proactive assessment and clear regulatory frameworks are essential for ensuring physician competence and patient safety as the medical workforce ages.
More Related Videos
Related Concept Videos
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.